Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
— 11 份获得认可的摘要，包括重申LUMRYZ满意度、偏好和临床益处的新数据 —
– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –
— 演讲强调了Avadel对解决发作性睡病护理差距的持续承诺—
DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.
都柏林，2024年5月22日（GLOBE NEWSWIRE）——专注于改造药物以改变生活的公司Avadel Pharmicals plc（纳斯达克股票代码：AVDL）今天宣布，将在2024年6月1日至5日的美国睡眠医学学会和睡眠研究学会第38届年度联席会议SLEEP 2024上展示11张海报和一份口头演讲，支持使用LUMRYZ作为发作性睡病治疗选择，在休斯顿。
译文内容由第三方软件翻译。